Targeting ERBB2 mutations in solid tumors: biological and clinical implications

Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing results f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: Cousin, Sophie, Khalifa, Emmanuel, Crombe, Amandine, Laizet, Yech’an, Lucchesi, Carlo, Toulmonde, Maud, Le Moulec, Sylvestre, Auzanneau, Céline, Soubeyran, Isabelle, Italiano, Antoine
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Letter to the Editor
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6019715/
https://ncbi.nlm.nih.gov/pubmed/29941010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0630-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky